I think it could do really well as more regional deals are realised and it can settle in a very nice range for shareholders. Everything ultimately depends on trial results which are not yet fully guaranteed.
My longer term hope is for their dmx700 pipeline for chronic obstructive pulmonary disease (COPD) which is horribly debilitating for sufferers and distressing to witness. (I need to update myself exactly where it's at trial-wise.)
Based solely on my own thoughts successful treatment of COPD would multiply the company value several times beyond where it will settle for FSGS success only.
Definitely a longer term hope.
dyor - not financial advice - my musings only
DXB - Research & Valuation, page-131
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.0¢ |
Change
-0.010(2.50%) |
Mkt cap ! $217.3M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 40.5¢ | 39.0¢ | $370.0K | 934.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 25531 | 39.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 7985 | 1 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| DXB (ASX) Chart |